trending Market Intelligence /marketintelligence/en/news-insights/trending/uic-uHsgfdxUMOcvF-hgrw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us
In This List

Kaleido BioSciences seeking up to $100M in Nasdaq IPO

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help


Kaleido BioSciences seeking up to $100M in Nasdaq IPO

Kaleido BioSciences Inc. is planning to raise up to $100 million in an IPO on Nasdaq.

The Lexington, Mass.-based biotechnology company, whose pipeline includes medicines for infections caused by drug-resistant bacteria, heart and kidney diseases, and diarrhea, plans to list its shares on the Nasdaq Global Select Market under the symbol KLDO.

Goldman Sachs & Co. LLC, J.P. Morgan Securities LLC, Morgan Stanley & Co. LLC and Canaccord Genuity LLC are the underwriters of the IPO and will have an option to buy additional shares in the offering.